Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06183931 | Study of ALXN2220 Versus Placebo in Adults With ATTR-CM | PHASE3 | ACTIVE NOT_RECRUITING | 1,181 | — | — | Jan 11, 2024 | Oct 5, 2027 | Feb 23, 2026 | 212 | United States, Argentina +25 |
| Arm | Type | Description |
|---|---|---|
| ALXN2220 | EXPERIMENTAL | Participants will receive weight-based dose of ALXN2220 via intravenous (IV) infusion every 4 weeks (q4w) for at least 24 months up to a maximum of 48 months. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo via IV infusion q4w for at least 24 months up to a maximum of 48 months. |
| Name | Type | Description |
|---|---|---|
| ALXN2220 | DRUG | Participants will receive ALXN2220 via IV infusion. |
| Placebo | DRUG | Participants will receive placebo via IV infusion. |
Inclusion Criteria: * Diagnosis of ATTR-CM with either wild-type or variant TTR genotype * End-diastolic interventricular septal wall thickness ≥ 12 mm on echocardiography measured at Screening * NT-proBNP \> 2000 pg/mL at Screening * Treatment with a loop diuretic for at least 30 days prior to Scr...